F023 Great Debates in Medical Dermatology
DESCRIPTION
This session will highlight the experiences of leaders in our field as they discuss the challenges involved with caring for sick patients. There is much to learn in medical dermatology and many of the management strategies we employ in clinical practice lack evidence. This session focus will be on complex conditions including neutrophilic dermatoses, SJS/TEN, and psoriasis with an emphasis on "big picture" challenges in dermatology, such as cost-concoius practice. Our expert panel will debate and discuss how they approach these conditions and the evidence supporting their management.
LEARNING OBJECTIVES
Formulate an evidence-based approach to patients with complex skin conditions and identify how "lumping" versus "splitting" can improve diagnosis and management.
Analyze the costs of dermatologic care in patients with complex skin conditions.
Summarize expert consensus in the management of complex medical dermatology patients.
SCHEDULE
1:00 PM
Introduction
Bridget Shields, MD, FAAD
1:10 PM
Psoriasis
Aaron Mangold, MD, FAAD
1:15 PM
Psoriasis
Arash Mostaghimi, MD, MPH, FAAD
1:20 PM
Debate and Panel Discussion
1:45 PM
Introduction
Bridget Shields, MD, FAAD
1:50 PM
SJS/TEN
Karolyn Wanat, MD, FAAD
1:55 PM
SJS/TEN
Robert Micheletti, MD, FAAD
2:00 PM
Debate and Panel Discussion
2:25 PM
Introduction
Bridget Shields, MD, FAAD
2:30 PM
Neutrophilic Dermatoses
Misha Rosenbach, MD, FAAD
2:35 PM
Neutrophilic Dermatoses
Dirk Michael Elston, MD, FAAD
2:40 PM
Debate and Panel Discussion
2:50 PM
Q&A
DIRECTOR
Bridget Shields, MD, FAAD
SPEAKERS
Dirk Michael Elston, MD, FAAD
Aaron Mangold, MD, FAAD
Robert Micheletti, MD, FAAD
Arash Mostaghimi, MD, MPH, FAAD
Misha Rosenbach, MD, FAAD
Karolyn Wanat, MD, FAAD
HANDOUTS
DISCLOSURES
Dirk Michael Elston, MD, FAAD
No financial relationships exist with ineligible companies.
Aaron Mangold, MD, FAAD
arGEN-X – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Atlas Med – Other(Patent royalties or other compensation for Intellectual Property Rights); Boehringer Ingelheim – Consultant(Honoraria); Bristol Myers Squibb – Investigator(Grants/Research Funding); clarivate – Consultant(Grants/Research Funding); Dragonfly Therapeutics – Consultant (1099 relationship)(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); EMD Serono – Investigator(Grants/Research Funding); Incyte Corporation – Investigator(Grants/Research Funding); Insmed – Investigator(Grants/Research Funding); Janssen Global Services, LLC – Consultant(Honoraria); Kyowa Kirin – Investigator(Grants/Research Funding); Merck – Investigator(Grants/Research Funding); miRagen Therapeutics, Inc. – Investigator(Grants/Research Funding); Novartis – Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Priovant – Investigator(Grants/Research Funding); Priovant Therapeutics – Other(Patent royalties or other compensation for Intellectual Property Rights); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Scitech Development – Investigator(Grants/Research Funding); Solgenix, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
Robert Micheletti, MD, FAAD
Boehringer Ingelheim – Investigator(Grants/Research Funding); Cabaletta Bio – Investigator(Grants/Research Funding); Vertex Pharmaceuticals, Inc. – Consultant(Fees);
Arash Mostaghimi, MD, MPH, FAAD
AbbVie – Consultant(Fees); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Advisory Board(Fees), Investigator(Grants/Research Funding); Equillium, Inc. – Consultant(Fees); Hims – Advisory Board(Honoraria); Incyte Corporation – Investigator(Grants/Research Funding); Indomo – Consultant (1099 relationship)(Fees); Legacy Healthcare – Consultant (1099 relationship)(Fees); Olaplex – Advisory Board(Fees); Pelage Pharmaceuticals – Advisory Board(Fees); Pfizer Inc. – Advisory Board(Fees), Consultant(Fees); Q32 Bio Inc. – Consultant (1099 relationship)(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees);
Misha Rosenbach, MD, FAAD
Google Ventures – Consultant (1099 relationship)(Honoraria); J&J Innovative Medicine – Consultant(Honoraria); Merck & Co., Inc – Consultant(Honoraria); OpenEvidence – Advisory Board(Other Financial Benefit); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding);
Bridget Shields, MD, FAAD
Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria); UpToDate, Inc – Other(Honoraria);
Karolyn Wanat, MD, FAAD
No financial relationships exist with ineligible companies.